Bioxytran, Inc.
Needham
Bioxytran, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing innovative therapies for hypoxia-related conditions, viral infections, and degenerative diseases. The company leverages advanced carbohydrate-based drug design and galectin inhibitor technology to create treatments aimed at stroke, wound healing, and infectious diseases like COVID-19. Its pipeline includes promising drug candidates such as oxygen-carrying therapeutics, antiviral agents and anti-metastasis for cancer designed to address critical unmet medical needs and improve patient outcomes.
